GILEAD SCIENCES, INC. Cash Equivalents, at Carrying Value
GILEAD SCIENCES, INC. (GILD) had Cash Equivalents, at Carrying Value of $4.10 billion as of 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2018-08-06
- 2018-06-30: Cash Equivalents, at Carrying Value $4.10B.
- 2018-03-31: Cash Equivalents, at Carrying Value $195.00M.
- 2017-12-31: Cash Equivalents, at Carrying Value $481.00M; Cash Equivalents, at Carrying Value as first filed $5.20B.
- 2017-09-30: Cash Equivalents, at Carrying Value $9.52B.
| Period end | Cash Equivalents, at Carrying Value | Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2018-06-30 | $4.10B 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $195.00M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $481.00M 10-Q · filed 2018-08-06 | $5.20B 10-K · filed 2018-02-27 |
| 2017-09-30 | $9.52B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $6.88B 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $8.06B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $5.71B 10-K · filed 2018-02-27 | |
| 2015-12-31 | $10.16B 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |